The focus is on lowering the price of the drug rather than improving the registration, shortening the time and effectiveness are insignificant." "There was no discussion with the consultative body. It's hard to gather opinions from the industry." The KRPIA expressed strong opposition to the government's plan to strengthen access to new drugs.

Rather, it is pointed out that it will reduce patient accessibility.

According to KPRIA on the 9th, the "plan to enhance patient access to high-priced severe disease treatments and strengthen salary management" reviewed by the Health Insurance Policy Review Committee of the MOHW on the 20th of last month focuses only on strengthening follow-up manage